Comparison
GHRP-2 vs. Tirzepatide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Growth
Metabolic
CAS no.
158861-67-7
2023788-19-2
Molecular weight
817.93 g/mol
4813 g/mol
Half-life
0.5 h
116 h
Sequence
D-Ala-D-2-Naphthyl-Ala-Ala-Trp-D-Phe-Lys-NH2YXEGTFTSDYSIYLDKIAQKAFVQWLIAGGPSSGAPPPSMechanism of action
GHRP-2
GHRP-2 binds with high affinity to the GH secretagogue receptor (GHSR-1a) in the pituitary and hypothalamus. Activation leads to rapid release of pulsatile growth hormone. Unlike GHRH, GHRP-2 acts via a separate pathway and can be combined synergistically with GHRH to elicit maximal GH responses in provocation tests.
Tirzepatide
Tirzepatide is a 39-amino-acid peptide acting as a dual agonist at the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. Activation of both incretin receptors via G-protein-coupled signalling raises insulin secretion in a glucose-dependent manner, lowers glucagon secretion and delays gastric emptying. Centrally, satiety perception is modulated. A fatty-acid side chain binds to serum albumin and extends the half-life to about five days.
Evidence base
Highest evidence
Human trial
Human RCT
Studies
4
3
of which in humans
4
3
Effects recorded
3
4
Open conflicts
0
0
Documented adverse events
1
2